Publications by authors named "C L Ackermann"
Introduction: cardiovascular magnetic resonance imaging is considered the standard of care for many clinical cardiovascular applications. Magnetic resonance imaging is a scarce resource in sub-Saharan Africa, with a paucity of cardiac magnetic resonance imaging clinical services and research. The aim of this audit was to review the cardiac magnetic resonance imaging service provided at a public tertiary hospital in Cape Town, Western Cape Province, South Africa.
View Article and Find Full Text PDFThe thalamus-L-sign in hypoxic-ischemic injury likely reflects secondary circuit injury and is only a feature on delayed magnetic resonance imaging in children with established cerebral palsy: reply to Merhav et al.
Pediatr Radiol
November 2024
Purpose: The IL-6 receptor inhibitor tocilizumab reduces mortality and morbidity in severe cases of COVID-19 through its effects on hyperinflammation and was approved as adjuvant therapy. Since tocilizumab changes the levels of inflammatory markers, we aimed to describe these changes in patients treated with tocilizumab, analyse their value in predicting death and bacterial superinfection and determine their influence on mortality rates.
Methods: A retrospective analysis of 76 patients who were treated with tocilizumab for severe COVID-19 in 2020 and 2021 was conducted.
Article Synopsis
- Chronic HCV infection can lead to serious immune complications like B cell dyscrasias, and while antiviral therapy has reduced liver damage, its effects on these complications are still unclear.
- Researchers sequenced B cell receptors in patients with chronic HCV and those who achieved sustained virological response (SVR) after treatment, identifying patterns in neutralizing antibodies and comparing them to lymphoma data.
- Findings indicated that specific mutations in B cell receptors associated with high neutralizing activity were also found in lymphoma cases, suggesting a connection between the immune response to HCV and the persistence of potential lymphoma-like cells even after successful treatment.
Introduction: The safety and efficacy of first-line durvalumab in PS2 patients with advanced NSCLC is unknown. Here, we present the primary analysis of first-line durvalumab in PS2 patients, unsuitable for combination chemotherapy.
Methods: In this single-arm, multicenter, phase II trial patients with PD-L1 positive (tumor proportional score ≥25%), advanced NSCLC with PS2, received four-weekly durvalumab 1500 mg.